Different cell types within myeloma have varying susceptibilities to different drug therapies, and some cells will not respond to some treatments, explains Daniel G. Coit, MD, from Memorial Sloan-Kettering Cancer Center in this video from the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers dedicated to improving the quality and effectiveness of care for cancer patients. For more information on melanoma and other cancers, including the NCCN Guidelines for Patients, visit www.NCCN.com.
Link to this comment:
All Comments (0)